Response of refractory osteosarcoma to thalidomide and celecoxib.
Tsai
Yu-Chieh
YC
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Wu
Chen-Tu
CT
Hong
Ruey-Long
RL
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D000068579:Celecoxib; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D006615:Hip / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology*; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D011720:Pyrazoles; D013449:Sulfonamides; D013792:Thalidomide; D000068579:Celecoxib